Safety and Efficacy of IM21 Car-t Cells in Patients With Recurrent or Refractory BCMA Positive Multiple Myeloma
NCT03711864
·
clinicaltrials.gov ↗
PHASE1
Phase
UNKNOWN
Status
15
Enrollment
OTHER
Sponsor class
Conditions
Multiple Myeloma
Interventions
BIOLOGICAL:
IM21 CAR-T cells
Sponsor
Peking Union Medical College Hospital
Collaborators
[object Object]